Menu

Home
About Us
Our Technology
SirVir
- Aposense subsidiary in the field of respiratory viral infections
ATT-11T: Anti cancer pro-drug
- On June 1st 2020 Aposense signed an agreement to license out the ATT-11T to Processa Pharmaceuticals
News
Contact Us

Close



Search for:

SirVir announces COVID-19 accelerated development program

February 5 2020

SirVir, an Aposense subsidiary, announces the accelerated development of a treatment for the COVID-19

News

Contact Us

Telephone: + 972.73.239.7600
Fax: +972.3.921.57.14
E-mail: info@aposense.com

Careers

Latest news

Prof. Roger Kornberg mentions SirVir’s breakthrough results and applicability of the platform in an interview for Ynet.
7 Jan 2021
Aposense enters into an out-licensing agreement with Processa Pharmaceuticals
1 Jun 2020
SirVir obtained positive results in pre-clinical experiment against COVID-19
26 Apr 2020

Aposense © 2021. Privacy Policy

Home
About Us
▼
Our Technology
SirVir
▼
- Aposense subsidiary in the field of respiratory viral infections
ATT-11T: Anti cancer pro-drug
▼
- On June 1st 2020 Aposense signed an agreement to license out the ATT-11T to Processa Pharmaceuticals
News
Contact Us

Skip to content

Accessibility Tools

Increase Text
Decrease Text
Grayscale
High Contrast
Negative Contrast
Light Background
Links Underline
Readable Font
Reset